Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
4.300
-0.160 (-3.59%)
At close: Mar 31, 2025, 4:00 PM
4.454
+0.154 (3.59%)
After-hours: Mar 31, 2025, 7:29 PM EDT

Jasper Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
20.4217.0816.5711.414.8
Upgrade
Research & Development
55.8251.7934.6325.4215.88
Upgrade
Operating Expenses
76.2468.8651.236.8320.68
Upgrade
Operating Income
-76.24-68.86-51.2-36.83-20.68
Upgrade
Interest & Investment Income
5.065.20.7--
Upgrade
Other Non Operating Income (Expenses)
-0.09-0.827.09-3.08-10.99
Upgrade
EBT Excluding Unusual Items
-71.27-64.48-43.41-39.91-31.67
Upgrade
Other Unusual Items
-0.025.739.28-
Upgrade
Pretax Income
-71.27-64.47-37.69-30.64-31.67
Upgrade
Net Income
-71.27-64.47-37.69-30.64-31.67
Upgrade
Net Income to Common
-71.27-64.47-37.69-30.64-31.67
Upgrade
Shares Outstanding (Basic)
1510410
Upgrade
Shares Outstanding (Diluted)
1510410
Upgrade
Shares Change (YoY)
39.72%186.15%220.19%558.67%-
Upgrade
EPS (Basic)
-4.89-6.18-10.33-26.89-183.08
Upgrade
EPS (Diluted)
-4.89-6.18-10.33-26.89-183.08
Upgrade
Free Cash Flow
-63.15-52.33-46.43-36.11-18.27
Upgrade
Free Cash Flow Per Share
-4.33-5.01-12.73-31.69-105.60
Upgrade
EBITDA
-74.87-67.75-50.22-36.46-
Upgrade
D&A For EBITDA
1.371.110.980.38-
Upgrade
EBIT
-76.24-68.86-51.2-36.83-20.68
Upgrade
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q